Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANACEA: MT-601 in Pancreatic Cancer
NCT06549751Phase 1Not yet recruiting
- Sponsor
- Marker Therapeutics, Inc.
- Start
- Jul 2026
- Primary completion
- Jul 2028
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of neldaleucel in pancreatic cancer (PC) (5 arms), sponsored by Marker Therapeutics, Inc. Primary endpoint: Maximum Tolerated Dose at 24 months. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
neldaleucel
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06549751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06549751.